ERBISOL, solution for injections, ampules 2ml #10

ERBISOL, solution for injections, ampules 2ml #10

$44.00

Highly effective drugs of a new generation with an original mechanism of action. A characteristic feature of ERBISOL products is the original mechanism of action, according to which they act not so much on the disease as on the whole organism, activating the controlling systems of the body responsible for the search for and elimination of pathological changes. One of the main such monitoring systems is the immune system. The drugs specifically activate the immune system, the effectiveness of which manifests itself primarily through the action of the macrophage link, which contributes to the repair of damaged cells and the restoration of the functional activity of organs and tissues, and also through the N- and T-killers responsible for the destruction of abnormal cells and tissues.

  • Description
  • Additional information
  • Doses and Uses
  • Shipping & Payment
  • Reviews (0)

Description

ERBISOL. A characteristic feature of ERBISOL products is the original mechanism of action, according to which they act not so much on the disease as on the whole organism, activating the controlling systems of the body responsible for the search for and elimination of pathological changes. One of the main such monitoring systems is the immune system.

The drugs specifically activate the immune system, the effectiveness of which manifests itself primarily through the action of the macrophage link, which contributes to the repair of damaged cells and the restoration of the functional activity of organs and tissues, and also through the N- and T-killers responsible for the destruction of abnormal cells and tissues.

ERBISOL products in their composition contain low-molecular “signal” fragments of membrane glycoproteins performing the function of “markers of the physiological state of cells”, which, in pathological disturbances of homeostasis, activate the natural evolutionarily formed control systems of the body responsible for the search for and elimination of pathological changes in organs and tissues.

One such system is the immune system.

ACTIVE SUBSTANCES ERBISOL: a complex of natural non-protein low-molecular organic compounds of non-hormonal origin, derived from animal embryonic tissue, contains oligopeptides and glycopeptides (generally 0.07-1.0 mg), nucleotides, amino acids;
AUXILIARY SUBSTANCES: р-р 0,9% sodium chloride isotonic.
SPECIFICITY of IMMUNOMODULATING PROPERTIES of ERBISOL® products:

  • activate macrophage cells involved in the repair of damaged cells and regeneration of organs and tissues with the restoration of their functional activity;
  • activate the killer series cells (N- and T-killers and cytotoxic T-lymphocytes CD8 ), responsible for the destruction of damaged cells that are unable to regenerate, or abnormal cells (mutant, malignant, virus carriers, etc.) and tissues;
  • are immunocorrectors: they normalize the activity of Th1 and Th2 lymphocytes and restore the balance of cytokines, thereby harmonizing the state of cellular and humoral immunity, as well as inhibiting the course of autoimmune and allergic processes.

Accelerate the destruction of abnormal and the restoration of damaged cells and tissues. ERBISOL® products ONLY affect unbalanced systems, affected organs and tissues and remain practically indifferent to a healthy organism without causing side effects, i.e. drugs are harmless, do not lead to drug poisoning in case of overdoses or long-term use. Excellent means for disease prevention.
Increase the protective and adaptive functions of the body.
Will help to realize your physiological potential for a full-fledged way of life.

ERBISOL, as an immunomodulator, equally affects cells as a macrophage, and the killer series (N- and T-killers), has immunocorrecting properties. It is intended for wide application.

The exclusive rights to ERBISOL products are protected in 20 countries of the world on the basis of international applications PCT / UA93 / 00003 and PCT / UA93 / 00004, including:
European Patent No. 0673652, No. 0673653, US Patents No. 08/397287, No. 08/397288, No. 2041715, No. 2041715 of Ukraine, No. 2164 of Ukraine, No. 2163, of Belarus No. 2039, No. 2040, of Poland No. 173321, No. 173302, of Bulgaria No. 61679 , No. 61680, ….

PHARMACOLOGICAL PROPERTIES ERBISOL:
Pharmacodynamics. Pharmacological activity of the preparation is determined by the content of low-molecular biologically active peptides, which activate natural, evolutionarily formed control systems of the body, responsible for the search and elimination of pathological changes. Erbisol activates the immune system to accelerate the restoration of damaged and destroy abnormal cells and tissues. The main immunomodulatory effect of the drug is manifested primarily through the action on the macrophage link responsible for the repair of damaged cells and restoration of the functional activity of organs and tissues, as well as through NK cells (CD316 56 ) and T-killers (CD3 16 56 ) responsible for the destruction of damaged cells incapable of regeneration, or abnormal cells (mutant, malignant, virus-carrying cells, etc.) and tissues.

INDICATIONS ERBISOL:

  • gastroenterology: hepatitis of various etiologies (including viral, toxic and medicamentous hepatitis caused by the use of antibiotics, interferons, chemotherapy and other powerful drugs that cause side effects), reactive hepatitis, steatohepatosis, liver cirrhosis, gastric and duodenal ulcer, erosive gastroduodenitis, nonspecific ulcerative colitis;
  • Toxicology: Erbisol enhances the detoxification function of the liver;
  • endocrinology: diabetes, autoimmune thyroiditis;
  • therapy: nonspecific lung diseases (pneumonia, chronic bronchitis), pulmonary tuberculosis, metabolic dystrophy, chronic fatigue syndrome, angiopathy, to improve microcirculation, tone normalization and vascular blood filling. Erbisol is used in the complex treatment of people affected by the effects of radiation exposure and environmental pollution, the drug has pronounced adaptive-corrective properties when combining the above pathologies, increasing the compensatory and protective functions of the body;
  • allergology: allergic and autoimmune diseases, including asthma, atopic dermatitis and atopic rhinoconjunctivitis;
  • gerontology: functional insufficiency, associated with age-related disorders of the liver, immune, nervous and cardiovascular systems. To increase physical activity and eliminate asthenic syndrome, to increase potency;
  • stomatology: periodontitis;
  • surgery and traumatology: traumatic, postoperative and purulent-septic wounds, fractures (to accelerate the consolidation of bone fragments), trophic ulcers of various etiologies, diabetic angiopathies, pressure ulcers;
  • oncology: in surgical treatment for the prevention of metastasis and rapid wound healing. With chemo- and radiotherapy, Erbisol is used in the complex as an accompaniment preparation, as a hepato-, immunoprotector and reparant, and in the rehabilitation and intercourse period as an immunocorrector and a reparant for activating the antitumor protection of the organism.

CONTRAINDICATIONS: Individual intolerance.
SIDE EFFECTS: Erbisol is well tolerated by patients. When using the drug, an exacerbation of the chronic inflammatory process in the first 2-5 days of therapy is possible, which in most cases is a stage of the medical process; possible allergic reactions, including rash, itching.
STORAGE CONDITIONS: At a temperature of 4-12 °C (39-53 °F). During storage, opalescence may occur.


external

Additional information

Weight 150 g
Forms of release

Solutions for injections

Volume / Weight

2 ml #10

Packing

Ampoules

Manufacturer

ERBIS

Country/Region of Manufacture

Ukraine

APPLICATION:
dosing and treatment is determined by the doctor individually, depending on the nature and course of the disease (as a monotherapy or as part of a comprehensive treatment).

  • Erbisol is administered in/m, in/v, in/a, intraperitoneally or inside the tumor daily adult 2-4 ml. The course of treatment is 20 days and, considering the chronorhythm of the body, a single administration is desirable to be prescribed in the evening, before going to bed, at 21:00-24:00, 2-3 hours after meals. In the case of a double injection, additionally appoint in the morning at 6:00-9:00 1-2 hours before meals. The average exchange rate is 40-80 ml.
  • With reactive hepatitis, autoimmune, allergic diseases, adults are prescribed daily 2 ml of in/m for 20 days.
  • For wounds, periodontitis in the first 10 days, adults are prescribed in/v ml of 4 ml, and in the next 10 days, if necessary, 2 ml each. When generalized periodontitis is additionally prescribed infiltration into the gum or application or Erbisol electrophoresis from the anode ( ) on the gums.
  • Patients with COPD and asthma with respiratory failure of degree I adults Erbisol injected in/m 2 ml once a day at 21:00-24:00 for the first 3 days, then 5 days 2 ml twice a day at 16:00 -18:00 and 21:00-24:00 and 7 days – 2 ml once a day at 21:00-24:00. The course dose is 40 ml.
  • Patients with COPD and asthma with respiratory failure grade II adults Erbisol injected in/m for the first 3 days of 2 ml once a day at 21:00-24:00, and in the next 10 days – 2 ml twice: in 16:00-18:00 and 21:00-24:00, then within 7 days – 2 ml at 21:00-24:00. The course dose is 60 ml.
  • In COPD and asthma, accompanied by deep and irreversible changes in the functions of external respiration with respiratory failure of grade III, pulmonary tuberculosis for treatment requires at least 80 ml of Erbisol. Patients in this group of drugs are prescribed in/m 2 ml twice: at 16:00-18:00 and 21:00-24:00. The course of treatment is 20 days. The proposed method of treatment complements the stepwise scheme of basic therapy.
  • When hepatitis, steatohepatosis, liver cirrhosis, ulcerative lesions of the stomach and duodenum, erosive gastroduodenitis, ulcerative colitis, metabolic dystrophies, tissue damage, fractures (to accelerate the consolidation of bone fragments), trophic ulcers of various etiologies, bedsores, as well as in rehabilitation and recovery therapy, to increase physical activity, adaptive-correcting and protective functions of the body, to eliminate asthenic syndrome, chronic fatigue syndrome and, the adult drug is used in/m 2 ml daily 2 times a day: at 6:00-9:00 and 21:00-24:00 for 20 days, or for the first 3 days 2 ml of the drug is administered 1 time per day at 21:00-24:00, and in the next 10 days 2 ml are administered 2 times a day: at 6:00-9:00 and 21:00-24:00, then for 7 days – 2 ml at 21:00-24:00.
  • With diabetes, autoimmune thyroiditis Erbisol is prescribed daily 2 times a day for 2 ml – in the morning at 6:00-9:00 and in the evening at 21:00-24:00 in/v or in/m for 20 days.
  • In case of oncological diseases, as a preparation for the accompaniment and rehabilitation of radiotherapy, Erbisol is prescribed daily for adults 2 ml 2 times a day in the morning at 6:00-9:00 and in the evening at 21:00-24:00 h for 20 days, 1-2 days before the course of radiotherapy.
  • In chemotherapy adults Erbisol is prescribed daily starting 2-3 days before the chemotherapy course, once a day in the evening at 21:00-24:00, 2 ml in/m, during chemotherapy and ending on the 7-12th day after the course of chemotherapy (15-25 days in total), and also 2 ml in the morning in the morning at 6:00-9:00, starting 1-2 days before the course of chemotherapy, during chemotherapy and ending with a 3-7- day after the course of chemotherapy. That is, on the 1st day and the last 4-7 days of the Erbisol course, you can prescribe 2 ml 1 time per day in the evening at 21:00-24:00. On the days of receipt of chemotherapy, instead of the morning intravenous injection of 2 ml of the Erbisol preparation, it is advisable to administer 4-16 ml of Erbisol (depending on the regimen and the dose of chemotherapy drugs) fractional, just prior to administration of each cytostatic and in the same way, i.e., in/a, inside the tumor or intraperitoneally, and at 17:00 in addition to in/m inject 2 ml Erbisol. For example, with intravenous drip infusion chemotherapy, Erbisol 2 ml is injected intravenously before each infusion of 200 ml of the solution chemotherapy drug. With in/a infusion of chemotherapy – the drug Erbisol is administered in the same way in/a. With regional chemotherapy, prior to administration of the chemotherapy regimen, 4 ml Erbisol is injected in the same way or inside the tumor. Additional intravenous injection of 2 ml of Erbisol at 17:00 appoint another 2-3 days after the administration of significant doses of chemotherapy. When carrying out chemotherapy with drugs that affect the hormonal status of the patient, Erbisol is prescribed no earlier than 3 hours after the use of such drugs.
STANDART SHIPPING WORLDWIDE
WEIGHT (kg) COST ($US) ESTIMATED

DELIVERY TIME

TRACKING
0 - 0.199 6.50 15 - 21 working days Available
0.200 - 0.250 8.00 15 - 21 working days Available
0.251 - 0.500 14.00 15 - 21 working days Available
0.501 - 1.000 20.00 15 - 21 working days Available
1.000 - 2.000 25.00 15 - 21 working days Available

PAYMENT

  • We accept Visa, MasterCard via AdvCash & Payeer (there are problems with the possibility).
  • We accept SEPA, BACS.
  • We accept RIA.
  • We accept Cryptocurrency.
  • PayPal.

Depending on the method of payment, additional Fees / VAT are charged.

And also there is a system of bonuses that you can spend on your next purchases.

Reviews

There are no reviews yet.


Only logged in customers who have purchased this product may leave a review.

You've just added this product to the cart: